The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus.
It is not clear whether elevated levels of the fibrinolytic inhibitor, plasminogen activator inhibitor-1 (PAl-1) in Type 2 diabetes mellitus are the result of obesity or coexistent atherosclerosis. Therefore the relationship between PAl-1 and insulin resistance, determined by the homeostasis model a...
| প্রধান লেখক: | , , , , |
|---|---|
| বিন্যাস: | Journal article |
| ভাষা: | English |
| প্রকাশিত: |
1993
|
| _version_ | 1826272401853251584 |
|---|---|
| author | Gough, S Rice, P McCormack, L Chapman, C Grant, P |
| author_facet | Gough, S Rice, P McCormack, L Chapman, C Grant, P |
| author_sort | Gough, S |
| collection | OXFORD |
| description | It is not clear whether elevated levels of the fibrinolytic inhibitor, plasminogen activator inhibitor-1 (PAl-1) in Type 2 diabetes mellitus are the result of obesity or coexistent atherosclerosis. Therefore the relationship between PAl-1 and insulin resistance, determined by the homeostasis model assessment (HOMA) was investigated in a group of 26 insulin-resistant, normotensive newly diagnosed Type 2 diabetic patients with a low probability of atherosclerosis. Compared with a normal control group, closely matched for body mass index (BMI), fibrinolytic activity was depressed in the diabetic patients due to elevated levels of the inhibitor PAl-1, 17.6 (11.1-28) vs 8.4 (4.9-14.1) IU ml-1, p < 0.001. PAl-1 was related to BMI, r = 0.59, p < 0.001 plasma insulin, r = 0.66, p < 0.001; insulin resistance, r = 0.54, p < 0.005 and urinary albumin excretion, r = 0.48, p < 0.01, but not HbA1c or fasting glucose. PAl-1 was not related to blood pressure or plasma triglyceride levels. This study suggests that at the time of diagnosis of Type 2 diabetes mellitus, elevated PAl-1 levels are already linked to other risk factors for vascular disease including hyperinsulinaemia, insulin resistance, and urinary albumin excretion, and this is not the result of obesity or coexistent atherosclerosis. |
| first_indexed | 2024-03-06T22:12:00Z |
| format | Journal article |
| id | oxford-uuid:52209ad8-d66c-4c8d-8b02-e47e46a065cb |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:12:00Z |
| publishDate | 1993 |
| record_format | dspace |
| spelling | oxford-uuid:52209ad8-d66c-4c8d-8b02-e47e46a065cb2022-03-26T16:23:41ZThe relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:52209ad8-d66c-4c8d-8b02-e47e46a065cbEnglishSymplectic Elements at Oxford1993Gough, SRice, PMcCormack, LChapman, CGrant, PIt is not clear whether elevated levels of the fibrinolytic inhibitor, plasminogen activator inhibitor-1 (PAl-1) in Type 2 diabetes mellitus are the result of obesity or coexistent atherosclerosis. Therefore the relationship between PAl-1 and insulin resistance, determined by the homeostasis model assessment (HOMA) was investigated in a group of 26 insulin-resistant, normotensive newly diagnosed Type 2 diabetic patients with a low probability of atherosclerosis. Compared with a normal control group, closely matched for body mass index (BMI), fibrinolytic activity was depressed in the diabetic patients due to elevated levels of the inhibitor PAl-1, 17.6 (11.1-28) vs 8.4 (4.9-14.1) IU ml-1, p < 0.001. PAl-1 was related to BMI, r = 0.59, p < 0.001 plasma insulin, r = 0.66, p < 0.001; insulin resistance, r = 0.54, p < 0.005 and urinary albumin excretion, r = 0.48, p < 0.01, but not HbA1c or fasting glucose. PAl-1 was not related to blood pressure or plasma triglyceride levels. This study suggests that at the time of diagnosis of Type 2 diabetes mellitus, elevated PAl-1 levels are already linked to other risk factors for vascular disease including hyperinsulinaemia, insulin resistance, and urinary albumin excretion, and this is not the result of obesity or coexistent atherosclerosis. |
| spellingShingle | Gough, S Rice, P McCormack, L Chapman, C Grant, P The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus. |
| title | The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus. |
| title_full | The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus. |
| title_fullStr | The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus. |
| title_full_unstemmed | The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus. |
| title_short | The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus. |
| title_sort | relationship between plasminogen activator inhibitor 1 and insulin resistance in newly diagnosed type 2 diabetes mellitus |
| work_keys_str_mv | AT goughs therelationshipbetweenplasminogenactivatorinhibitor1andinsulinresistanceinnewlydiagnosedtype2diabetesmellitus AT ricep therelationshipbetweenplasminogenactivatorinhibitor1andinsulinresistanceinnewlydiagnosedtype2diabetesmellitus AT mccormackl therelationshipbetweenplasminogenactivatorinhibitor1andinsulinresistanceinnewlydiagnosedtype2diabetesmellitus AT chapmanc therelationshipbetweenplasminogenactivatorinhibitor1andinsulinresistanceinnewlydiagnosedtype2diabetesmellitus AT grantp therelationshipbetweenplasminogenactivatorinhibitor1andinsulinresistanceinnewlydiagnosedtype2diabetesmellitus AT goughs relationshipbetweenplasminogenactivatorinhibitor1andinsulinresistanceinnewlydiagnosedtype2diabetesmellitus AT ricep relationshipbetweenplasminogenactivatorinhibitor1andinsulinresistanceinnewlydiagnosedtype2diabetesmellitus AT mccormackl relationshipbetweenplasminogenactivatorinhibitor1andinsulinresistanceinnewlydiagnosedtype2diabetesmellitus AT chapmanc relationshipbetweenplasminogenactivatorinhibitor1andinsulinresistanceinnewlydiagnosedtype2diabetesmellitus AT grantp relationshipbetweenplasminogenactivatorinhibitor1andinsulinresistanceinnewlydiagnosedtype2diabetesmellitus |